Policy

Chris Johnson, MBA, discusses how Medicaid incentives and higher primary-care pay can boost preventive pediatric care.

White House projects $600B in savings from MFN drug pricing plan, with major implications for GLP-1 access, Medicaid, and biologics.

Muhammad Bilal Abid, MD, discusses COVID prevention gaps, monoclonal antibodies, and infection risk in immunocompromised patients with CLL.

Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost savings and improved provider financial performance.

New executive order fast-tracks psychedelic therapy research for veterans, but VA rollout, DEA rescheduling, and insurance hurdles still loom.

Experts dismantled the assumption that direct-to-patient is a universal affordability solution, offering manufacturers a practical framework for deciding which model is actually right.

Lessons learned from developing an inferential model for predicting food insecurity yield essential insights and actionable steps for policy makers seeking to address health-related social needs.

This week, a Capitol hearing spotlights Medicare fraud gaps, reports warn of equity setbacks, community oncology boosts survival, and Medicaid work rules loom.

A new Commonwealth Fund report finds persistent racial health disparities nationwide despite coverage gains, with major gaps in care, access, and outcomes.

Specialty pharmacies play a critical role in connecting patients with assistance programs to combat growing financial complexities.

At AXS26, leaders shared the hard-won organizational, strategic, and operational lessons from rounds 1, 2, and 3 of the Medicare Drug Price Negotiation Program.

Policy experts discuss how PBM reforms came together, what changes are on the horizon, and what threats are looming for community oncology.

As pricing reforms like Most Favored Nation reshape global drug launches, patients may ultimately pay the highest price, said Dee Chaudhary of Clarivate.

Drug pricing transparency and easy discounts cut abandoned prescriptions, as federal policies put pressure on pharma, says Laura Jensen of GoodRx.

Justin Favaro, MD, discusses independent oncology models, ACA challenges, and strategies to reduce health care costs at IVBM Charlotte 2026.

House lawmakers questioned hospital CEOs over rising health care costs, consolidation, opaque billing, Medicaid cuts, and site neutrality.

Policy and market access experts break down the compounding forces reshaping drug pricing, PBM regulation, and manufacturer strategy heading into the 2026 midterms.

COA's annual conference hits Orlando April 28, focusing on AI, targeted therapy innovation, and state-level oncology advocacy, explains cochair Johnetta Blakely, MD, MS, MMHC.

The proposed rule on interoperability standards and prior authorization could lead to significant change in CMS.

A lengthy Ways and Means Committee hearing revealed extensive Medicare system exploitation and ignited partisan debates on fixing it.

New reports spotlight inequities—from Black maternal mortality to 988’s youth impact—as well as rising cancer risk and gaps in food aid.

Explore 5 FAQs on CDC opioid guidelines, including dosing, tapering, monitoring, and managed care strategies to reduce overdose risk.

The authors examined experiences with Pennsylvania’s implementation of opioid settlement funds, identifying 7 themes and highlighting opportunities to improve administration and ensure effective fund distribution.

The 2018 permanent authorization of dual-eligible special needs plans marked a significant long-term commitment by policy makers and coincided with substantial growth in plan offerings and enrollment.

Black Maternal Health Week spotlights disparities, Medicaid postpartum coverage gains, and ongoing policy efforts to reduce maternal mortality.